MRVI vs TWST
MRVI: Maravai LifeSciences produces critical reagents and manufacturing services for mRNA vaccines and therapies, with CleanCap and TriLink products serving large biotech and pharmaceutical customers. TWST: Twist Bioscience is a synthetic DNA synthesis platform company that enables the design and production of custom DNA molecules for drug development, diagnostics, and research applications.
Side-by-side fundamentals
| Metric | MRVI | TWST | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.10 | $94.21 | |
| Market cap as of 2026-07-23 | $1.8B | $5.8B | |
| Net margin as of 2026-07-23 | -51.1% | -19.9% | TWST higher |
| Gross margin as of 2026-07-23 | +29.3% | +52.1% | TWST higher |
| Operating margin as of 2026-07-23 | -82.2% | -33.9% | TWST higher |
| ROE as of 2026-07-23 | -44.7% | -17.5% | TWST higher |
| ROA as of 2026-07-23 | -13.0% | -12.5% | TWST higher |
| Debt / equity as of 2026-07-23 | 1.28 | 0.00 | TWST lower |
| Revenue growth (YoY) as of 2026-07-23 | -15.3% | +17.8% | TWST higher |
| Revenue CAGR (3y) SEC XBRL | -40.5% | n/a | |
| Beta as of 2026-07-23 | 0.56 | 2.14 | |
| 1-year return as of 2026-07-22 close | +180.6% | +162.9% | MRVI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.